Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F24%3A10478537" target="_blank" >RIV/00669806:_____/24:10478537 - isvavai.cz</a>
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2jwBLwiR66" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2jwBLwiR66</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2023.284858" target="_blank" >10.3324/haematol.2023.284858</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Popis výsledku v původním jazyce
The retrospective, multricenter EBMT study was performed to evaluate the incidence and outcome of CNS relapse after allogeneic transplantation in patients suffering from AML and ALL. Study included 7,991 patients: 5,724 (71.6%) AML, and 2,267 (28.4%), all patients were transplantedbetween 1996 and 2016. Ninety-one patients of the 7,991 (1.1%) experienced CNS relapse after allo-HSCT. The relapse was more frequent in ALL than in AML. CNS relapse was a rare event, however the prognosis was dismal. Around half the patients could achieve CR, but the OS remained low (8.2% in AML, 15.5% in ALL at 5 years). OS was better in isolated CNS (37.5% vs. 6.7% at 2 years).
Název v anglickém jazyce
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Popis výsledku anglicky
The retrospective, multricenter EBMT study was performed to evaluate the incidence and outcome of CNS relapse after allogeneic transplantation in patients suffering from AML and ALL. Study included 7,991 patients: 5,724 (71.6%) AML, and 2,267 (28.4%), all patients were transplantedbetween 1996 and 2016. Ninety-one patients of the 7,991 (1.1%) experienced CNS relapse after allo-HSCT. The relapse was more frequent in ALL than in AML. CNS relapse was a rare event, however the prognosis was dismal. Around half the patients could achieve CR, but the OS remained low (8.2% in AML, 15.5% in ALL at 5 years). OS was better in isolated CNS (37.5% vs. 6.7% at 2 years).
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Haematologica
ISSN
0390-6078
e-ISSN
1592-8721
Svazek periodika
109
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
IT - Italská republika
Počet stran výsledku
5
Strana od-do
2346-2350
Kód UT WoS článku
001263361100041
EID výsledku v databázi Scopus
2-s2.0-85197791112